Molecular Formula | C29H26ClFN4O4S |
Molar Mass | 581.06 |
Density | 1.381±0.06 g/cm3(Predicted) |
Melting Point | 144-146oC |
Boling Point | 750.7±60.0 °C(Predicted) |
Flash Point | 407.831°C |
Solubility | DMSO 100 mg/mL (172.09 mM); Water <1 mg/mL (<1 mM); Ethanol <1 mg/mL (<1 mM) |
Vapor Presure | 0mmHg at 25°C |
Appearance | solid |
Color | Yellow |
pKa | 6.34±0.19(Predicted) |
Storage Condition | 2-8°C(protect from light) |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. |
Refractive Index | 1.645 |
Use | An antineoplastic agent used in breast cancer research |
In vitro study | With ErbB-4 exceptions, Lapatinib is more than 300 times more selective for EGFR and ErbB-2 than for other tested kinases such as c-Src, MEK and ERK. Treatment with Lapatinib inhibited autophosphorylation of EGFR and ErbB-2 receptors in a dose-dependent manner, with IC50 values of 0.17 μm and 0.08 μm when acting on BT474 and HN5 cells, respectively. Lapatinib acts on EGFR-and ErbB-2-overexpressing tumor cells and inhibits EGFR and ErbB-2 autophosphorylation with about 10-fold lower potency than the purified enzyme. Lapatinib inhibited the growth of EGFR-and ErbB-2-overexpressing cells, whereas OSI-774 and Iressa (both EGFR-selective inhibitors) preferentially inhibited the growth of EGFR-overexpressing cells. The effect of Lapatinib on tumor cells is about 100 times higher than that on normal fibroblasts. ErbB-2 transfected mammary epithelial cells HB4a c5.2, the response sensitivity to Lapatinib was about 40 times higher than that of untransfected parental control cells HB4a. After culturing the HN5 cell population for about 2 weeks in a medium without Lapatinib, the cell growth was completely inhibited by a brief treatment with 30 μm Lapatinib. Concentrations> 3.3 μm inhibit growth by 50%. The growth was inhibited by 20% at a concentration of 0.37 μm. Another EGFR overexpressing cell A- 431 with a similar reaction to hn5. Lapatinib was similar to OSI-774 in inhibiting the growth of EGFR overexpressing cells. |
In vivo study | Lapatinib potently inhibits the growth of BT474 and HN5 human xenografts. Oral administration of 30 and 100 mg/kg Lapatinib twice daily to tumor-bearing mice inhibited tumor growth in a dose-dependent manner. Treatment at the 100 mg/kg dose completely inhibited tumor growth. At this dose, there was <10% tumor loss during 21 days of treatment. |
HS Code | 29349990 |